Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer - BeOne

Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)

BeOne Study ID

BGB-A317-309

ClinicalTrials.gov ID

NCT03924986

China Drug Trials ID

CTR20182534

Study Overview

Sex: All

Age: 18 Years / 75 Years

Accepts Healthy Volunteers? yes

Study Documents

Plain Language Summary

Study Overview

Sex: All

Age: 18 Years / 75 Years

Accepts Healthy Volunteers? yes

Study Documents

Plain Language Summary